InspireMD (NYSE:NSPR) CEO Buys $25,200.00 in Stock

InspireMD, Inc. (NYSE:NSPR) CEO Marvin Slosman acquired 21,000 shares of the stock in a transaction on Tuesday, May 12th. The shares were purchased at an average price of $1.20 per share, for a total transaction of $25,200.00. Following the transaction, the chief executive officer directly owned 3,556,658 shares in the company, valued at approximately $4,267,989.60. This trade represents a 0.59% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

InspireMD Price Performance

NSPR stock opened at $1.05 on Friday. The stock has a market capitalization of $49.18 million, a price-to-earnings ratio of -1.40 and a beta of 0.82. The business’s fifty day moving average price is $1.44 and its two-hundred day moving average price is $1.71. InspireMD, Inc. has a fifty-two week low of $1.02 and a fifty-two week high of $2.93.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on NSPR shares. Loop Capital set a $5.00 price target on InspireMD in a research report on Tuesday, February 24th. Maxim Group started coverage on InspireMD in a research report on Monday, February 2nd. They issued a “buy” rating and a $6.00 price target on the stock. Piper Sandler restated an “overweight” rating and issued a $3.00 price target (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Finally, Lake Street Capital set a $4.00 price target on InspireMD in a research report on Monday, May 4th. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $4.50.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of NSPR. Creative Planning bought a new position in shares of InspireMD in the second quarter worth $44,000. Raymond James Financial Inc. boosted its stake in InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock valued at $101,000 after buying an additional 10,000 shares in the last quarter. Rosalind Advisors Inc. boosted its stake in InspireMD by 0.6% in the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company’s stock valued at $5,196,000 after buying an additional 14,109 shares in the last quarter. Soleus Capital Management L.P. boosted its stake in InspireMD by 99.5% in the second quarter. Soleus Capital Management L.P. now owns 1,886,207 shares of the company’s stock valued at $4,282,000 after buying an additional 940,831 shares in the last quarter. Finally, Courier Capital LLC boosted its stake in InspireMD by 83.3% in the third quarter. Courier Capital LLC now owns 55,000 shares of the company’s stock valued at $133,000 after buying an additional 25,000 shares in the last quarter. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.